Krystal Biotech, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Krystal Biotech, Inc. (KRYS) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of $39.79 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-17
- Krystal Biotech, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was $39.79M, a 98.71% increase from fiscal 2024.
- Krystal Biotech, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was $20.02M, a 639.48% increase from fiscal 2023.
- Krystal Biotech, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was $2.71M.
- Krystal Biotech, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$29.39M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | $39.79M 10-K · filed 2026-02-17 |
| 2024-12-31 | $20.02M 10-K · filed 2026-02-17 |
| 2023-12-31 | $2.71M 10-K · filed 2026-02-17 |
| 2022-12-31 | -$29.39M 10-K · filed 2025-02-19 |
| 2021-12-31 | -$14.58M 10-K · filed 2024-02-26 |
| 2020-12-31 | -$6.75M 10-K · filed 2023-02-27 |
| 2019-12-31 | -$4.01M 10-K · filed 2021-03-01 |
| 2018-12-31 | -$2.29M 10-K · filed 2020-03-10 |
| 2017-12-31 | -$2.69M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |